• Ngugi M. Piero Department of Biochemistry and Biotechnology
  • Njagi M. Joan Department of Environmental Health, Kenyatta University, P. O. Box 43844-00100 Nairobi


Cancer is one of the most common causes of death, taking over 7 million lives each year globally. The global incidence is remarkably rising. Massive investments in research are also on the rise to unravel the genetic and molecular basis of cancer as a prerequisite to design of more effective treatment strategies. This review explores causes of cancer, its molecular basis and the treatment strategies. Future perspectives regarding research on cancer and envisaged milestones of management and/or treatment interventions are also explored.

Keywords: Carcinogens, Mutations, Proto-oncogenes, Tumor-suppressor genes


1. WHO. The Global Burden of Disease. 2004 Update. Geneva: World Health Organization; 2008.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward EM, Forman D. Global cancer statistics. CA: Cancer J Clin 2011;61(2):69-90.
3. Malcolm RA. Cancer. Imperial College School of Medicine: London, UK; 2001.
5. Sikora K. Developing a global strategy for cancer. Eur J Cancer 1999;35:24–31.
6. Klug WS, Cummings MR. Essentials of genetics. 5th Edition. Pearson Prentice Hall; 2010.
7. Clapp RW, Howe GK, Jacobs MM. Environmental and occupational causes of cancer a review of recent scientific literature”. Lowell center for sustainable production; 2005.
8. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83.
9. Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the swedish family-cancer database. Int J Cancer 2002;99:260–6.
10. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
12. Hunter T. Oncoprotein networks. Cell 1997;88:333–46.
13. Hesketh R. ed. The oncogene and tumor suppressor gene facts book. 2d ed. Academic Press; 1997.
14. Sherr CJ, McCormick F. The Rb and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
15. White R. Tumor suppressor pathways. Cell 1998;92:591‐2.
16. Planas-Silva MD, Weinberg RA. The restriction point and control of cell proliferation. Curr Opin Cell Biol 1997;9:768–72.
17. Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell 1997;88:315–21.
18. Mathon NF, Lloyd AC. Cell senescence and cancer. Nat Rev Cancer 2001;1:203–13.
19. Sherr CJ. Cell cycle control and cancer. Harvey Lect 2000;96:73–92.
20. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2000;2:910–7.
21. Taipale J, Beachy PA. The Hedgehog and Wnt signaling pathways in cancer. Nature 2001;411:349-54.
22. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837–51.
23. Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signalling through beta-catenin. Sci 2002;296:1644–6.
24. Wu H, Chang D, Huang C. Targeted-therapy for cancer. J Cancer Mol 2006;2:57–66.
25. Papac RJ. Origins of cancer therapy. Yale J Biol Med 2001;74:391–8.
26. Dunn FB. National cancer act: leaders reflect on 30 years of progress. JNCI J Natl Cancer Inst 2002;94(1):8-9.
354 Views | 785 Downloads
How to Cite
Piero, N. M., and N. M. Joan. “CANCER: A MOLECULAR CURSE?”. International Journal of Current Pharmaceutical Research, Vol. 7, no. 3, July 2015, pp. 1-3,
Review Article(s)